Please visit answersincme.com/URZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in esophageal carcinoma (EAC) discusses novel tests to predict the risk of progression from Barrett’s esophagus (BE) to EAC. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using novel prognostic stratification tests to predict the risk of progression from BE to EAC, Review the clinical support for prognostic tests that provide actionable information for identifying patients with BE who are at risk of progression to EAC; and Outline strategies to integrate novel prognostic tests into the surveillance algorithm for patients with BE who may be at risk of progression to EAC.

Please visit answersincme.com/860/27391-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in breast cancer discuss patient-centered strategies to optimize quality of life by implementing a proactive approach to adverse event management for HR+, HER2- mBC. Upon completion of this activity, participants should be better able to: Outline evidence-based clinical strategies to enhance a sequential therapeutic approach in real-world patient populations; and Identify proactive, patient-focused strategies to elevate survivorship for patients receiving ADCs for HR+, HER2- mBC.

Please visit answersincme.com/860/27391-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts illustrate how to sequence available therapies for HR+, HER2- metastatic breast cancer. Upon completion of this activity, participants should be better able to: Review the expert recommendations regarding a sequential approach to the use of ADCs for HR+, HER2- metastatic breast cancer (mBC) management; and Outline evidence-based clinical strategies to enhance a sequential therapeutic approach in real-world patient populations.

Please visit answersincme.com/860/27391-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts discuss how the available evidence informs sequencing strategies with antibody-drug conjugates for the optimization of care in HR+, HER2- metastatic breast cancer. Upon completion of this activity, participants should be better able to: Review the expert recommendations regarding a sequential approach to the use of ADCs for HR+, HER2- metastatic breast cancer (mBC) management; and Outline evidence-based clinical strategies to enhance a sequential therapeutic approach in real-world patient populations.

Please visit answersincme.com/RJB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in multiple myeloma discuss strategies for incorporating bispecific antibodies into the treatment of heavily pretreated relapsed/refractory multiple myeloma RRMM in the community setting. Upon completion of this activity, participants should be better able to: Review the role of bispecific antibodies in the current treatment landscape of RRMM; Discuss the clinical profiles of approved and late-stage emerging bispecific antibodies in heavily pretreated RRMM; Describe strategies to optimize outcomes with bispecific antibodies for the treatment of RRMM; and Outline practical considerations for incorporating bispecific antibodies into the treatment of heavily pretreated RRMM in the community setting. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/860/95483855-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss practical strategies for integrating antibody-drug conjugates in special populations with HER2-low advanced breast cancer and essential adverse event management approaches. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.

Please visit answersincme.com/860/95483855-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss antibody-drug conjugates in HER2-low advanced breast cancer, including current guideline recommendations and evolving treatment considerations to optimize individualized care. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.

Please visit answersincme.com/BCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses use of TROP2-directed antibody-drug conjugates for the management of hormone receptor–positive, HER2-negative metastatic disease. Upon completion of this activity, participants should be better able to: Identify the available TROP2-directed ADCs for management of HR+, HER2- metastatic breast cancer (mBC); Outline the efficacy and safety of available and emerging TROP2-directed ADCs for HR+, HER2- mBC; and Apply personalization factors to help identify the optimal therapy for each individual patient with HR+, HER2- mBC.

Please visit answersincme.com/860/95483855-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and pathology discuss the evolving classification of HER2 status in advanced breast cancer, including HER2 low and HER2 ultralow, and its impact on treatment decisions. Upon completion of this activity, participants should be better able to: Identify strategies to enhance the identification of HER2-low and -ultralow status in patients with advanced breast cancer; and Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer,

Please visit answersincme.com/BCK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myeloma discusses the latest data in anti-CD38 quadruplet regimens in newly diagnosed multiple myeloma. Upon completion of this activity, participants should be better able to: Identify the role of anti-CD38 monoclonal antibody (mAB)–based quadruplet regimens in the treatment landscape for newly diagnosed multiple myeloma (NDMM); Review the latest clinical data of anti-CD38 mAB-based quadruplet regimens for transplant-ineligible patients with NDMM; and Analyze evidence-based strategies for optimizing outcomes with anti-CD38 mAB-based quadruplet regimens in patients with transplant-ineligible NDMM.